“‘Semaglutide’ Tag”,2020-06-21 (gravitostat, tirzepatide, neuroscience, willpower)⁠:

Bibliography for tag longevity/glp/semaglutide, most recent first: 2 related tags, 138 annotations, & 48 links (parent).

• See Also
• Links
  • “Once-Weekly Semaglutide in Persons With Obesity and Knee Osteoarthritis”, Bliddal et al 2024
  • “Ozempic and Wegovy Ease Knee Osteoarthritis Pain in Large Study”
  • “‘Ozempic Changed My Life’: Do Diabetes Jabs Boost the Chances of Conception?”
  • “The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial”, Scirica et al 2024
  • “My Lukewarm Take on GLP-1 Agonists § My Own Experience”, George2024
  • “Sublingual Semaglutide”, Jolley2024
  • “Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data”, Wang et al 2024c
  • “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity”, Rodriguez et al 2024
  • “‘Skinny Jabs’: Weight-Loss Drugs Set for New Boom As Generic Liraglutide Versions Emerge”, Davis & Kollewe2024
  • “Does Liraglutide Alleviate Inflammation in Brain-Dead Donors? A Randomized Clinical Trial”, Custódio et al 2024
  • “Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes”, Perkovic et al 2024
  • “Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020^–₃2023”, Lee et al 2024
  • “Estimated Sustainable Cost-Based Prices for Diabetes Medicines”, Barber et al 2024
  • “Association of Semaglutide With Risk of Suicidal Ideation in a Real-World Cohort”, Wang et al 2024
  • “Randomized Open-Label Trial of Semaglutide and Dapagliflozin in Patients With Type 2 Diabetes of Different Pathophysiology”, Dwibedi et al 2024
  • “Central Glucagon-Like Peptide 1 Receptor Activation Inhibits Toll-Like Receptor Agonist-Induced Inflammation”, Wong et al 2024
  • “Oprah Winfrey’s Revelation about Using Weight-Loss Drugs Is a Game-Changer: Here’s Why”, Trepany2023
  • “Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series”, Richards et al 2023
  • “Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults With Overweight and Obesity in the US: A Real-World Evidence Study”, Rodriguez et al 2023
  • “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes”, Lincoff et al 2023
  • “Novo Nordisk Will Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, FLOW, Based on Interim Analysis”, Nordisk2023
  • “Her Insurance Refused to Pay for Wegovy, So She Sued: Many Employers and Government Programs Won’t Cover Costly Obesity Medications. A Lawsuit Is Challenging One Such Policy”, Robbins2023
  • “Ozempic Is Making People Buy Less Food, Walmart Says”, Case & Banjo2023
  • “Sharon Osbourne Quit Ozempic Because She’s ‘Too Skinny’”, Wickman2023
  • “A Revolution in Obesity Treatment”, Lingvay & Agarwal2023
  • “What Oprah Winfrey Said about Drugs Used for Weight Loss like Ozempic, Mounjaro”, Kindelan2023
  • “Semaglutide in Early Type 1 Diabetes”, Dandona et al 2023
  • “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults With Obesity”, Wharton et al 2023
  • “GWAS of Random Glucose in 476,326 Individuals Provide Insights into Diabetes Pathophysiology, Complications and Treatment Stratification”, Lagou et al 2023
  • “To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit Card Debts: Some People Pay More Than $10,000 a Year Out-Of-Pocket for Ozempic and Mounjaro”, Armour2023
  • “Semaglutide and Cancer: A Systematic Review and Meta-Analysis”, Nagendra et al 2023
  • “US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events”, Wong et al 2023
  • “Novo Boosted As Trial Shows Weight-Loss Wegovy Drug Has [Cardiovascular] Medical Benefits”, Fick & Skydsgaard2023
  • “Goodbye, Ozempic: A New Class of Drugs Is Transforming Obesity Care. They Are Not All the Same”, Engber2023
  • “Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement”, Jastreboff2023
  • “Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial”, Jastreboff et al 2023
  • “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: a Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA”, Rosenstock et al 2023
  • “Efficacy and Safety of Once-Daily Oral Semaglutide 25 Mg and 50 Mg Compared With 14 Mg in Adults With Type 2 Diabetes (PIONEER PLUS): a Multicentre, Randomised, Phase 3b Trial”, Aroda et al 2023
  • “Oral Semaglutide 50 Mg Taken Once per Day in Adults With Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial”, Knop et al 2023
  • “Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 Mg With Once-Weekly Semaglutide 2.4 Mg in Type 2 Diabetes: a Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial”, Frias et al 2023
  • “A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People With Overweight/Obesity”, Roux et al 2023
  • “Orforglipron (LY3502970), a Novel, Oral Non-Peptide Glucagon-Like Peptide-1 Receptor Agonist: A Phase 1a, Blinded, Placebo-Controlled, Randomized, Single-Dose & Multiple-Ascending-Dose Study in Healthy Participants”, Pratt et al 2023
  • “People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For Some, It’s a Startling Side Effect”, Blum2023
  • “What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know”, Reynolds2023
  • “I Lost 40 Pounds on Ozempic. But I’m Left With Even More Questions.”, Marcus2023
  • “Novo Nordisk A/S: Oral Semaglutide 50 Mg Achieved 15.1% Weight Loss in OASIS 1 Trial”, Nordisk2023
  • “Ozempic’s Next Act: People Taking the Drug for Weight Loss Say They Have Also Stopped Drinking, Smoking, Shopping, and Even Nail-Biting”, Zhang2023
  • “Effects of Liraglutide on Depressive Behavior in a Mouse Depression Model and Cognition in the Probe Trial of Morris Water Maze Test”, Seo et al 2023b
  • “Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study”, Yammine et al 2023
  • “A New Drug Switched Off My Appetite. What’s Left? Mounjaro Did What Decades of Struggle With Managing Weight Couldn’t. Welcome to the Post-Hunger Age”, Ford2023
  • “Why Experts Are Urging Swifter Treatment for Children With Obesity: Growing Research Has Shown That Intensive Interventions Are Needed, Scientists Say. Here Is Why Their Advice Is Changing”, Kolata2023
  • “Two-Year Effect of Semaglutide 2.4 Mg on Control of Eating in Adults With Overweight/obesity: STEP 5”, Wharton et al 2023
  • “Supplementary Appendix to Aroda Et Al 2032”, Anam2023
  • “Supplement To: Dandona P, Chaudhuri A, Ghanim H. Semaglutide in Early Type 1 Diabetes”, Ghanim2023
  • “Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial”, Saxena et al 2023
  • “Once-Weekly Semaglutide in Adolescents With Obesity”, Weghuber et al 2022
  • “Liraglutide Provides Cardioprotection through the Recovery of Mitochondrial Dysfunction and Oxidative Stress in Aging Hearts”, Durak & Turan2022
  • xKloc @ “2022-12-13”
  • “Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide—Semaglutide Users Also More Likely to Experience Weight Loss, Retrospective Study Suggests”, Dotinga2022
  • “Weight Loss TikTok Trend Triggers Shortage of Diabetic Medication”, Bui2022
  • “Dose Titration With the Glucagon-Like Peptide-1 Agonist, Liraglutide, Reduces Cue- and Drug-Induced Heroin Seeking in High Drug-Taking Rats”, Evans et al 2022
  • “Endpoints and Estimands: Understanding Trials of Weight-Loss Drugs”, Adler2022
  • “Two-Year Effects of Semaglutide in Adults With Overweight or Obesity: the STEP 5 Trial”, Garvey et al 2022
  • “Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic”, Variety2022
  • “Next Generation GLP-1/GIP/glucagon Triple Agonists Normalize Body Weight in Obese Mice”, Knerr et al 2022
  • “The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many Insurance Companies Refuse to Cover New Weight Loss Drugs That Their Doctors Deem Medically Necessary”, Kolata2022
  • “Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: the STEP 1 Trial Extension”, Wilding et al 2022
  • “Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia: Data from Pooled Double-Blind Randomized Controlled Trials and Nationwide Disease and Prescription Registers”, Nørgaard et al 2022
  • “Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial”, Rubino et al 2022
  • “Exenatide Once Weekly for Alcohol Use Disorder Investigated in a Randomized, Placebo-Controlled Clinical Trial”, Klausen et al 2022
  • “Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity: a Multicentre, Randomized, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial”, Lau et al 2021
  • “Anti-Obesity Drug Discovery: Advances and Challenges”, Müller et al 2021
  • “Wegovy™ Demonstrated Substantial and Sustained Weight Loss in Two-Year Study in Adults With Obesity”, Nordisk2021
  • “Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials”, Overgaard et al 2021
  • “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide With Semaglutide 2.4mg for Weight Management: a Randomized, Controlled, Phase 1b Trial”, Enebo et al 2021
  • “Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined”, Lundgren et al 2021
  • “The Gut-Brain Axis: Identifying New Therapeutic Approaches for Type 2 Diabetes, Obesity, and Related Disorders”, Richards et al 2021
  • “Semaglutide 2.4 Mg Once a Week in Adults With Overweight or Obesity, and Type 2 Diabetes (STEP 2): a Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial”, Davies et al 2021
  • “Anti-Interleukin-21 Antibody and Liraglutide for the Preservation of Β-Cell Function in Adults With Recent-Onset Type 1 Diabetes: a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial”, Herrath et al 2021
  • “Effect of Subcutaneous Semaglutide vs Placebo As an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial”, Wadden et al 2021
  • “Once-Weekly Semaglutide in Adults With Overweight or Obesity”, Wilding et al 2021
  • “The Effect of Semaglutide 2.4 Mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity”, Friedrichsen et al 2021
  • “Testing the Effects of the GLP-1 Receptor Agonist Exenatide on Cocaine Self-Administration and Subjective Responses in Humans With Cocaine Use Disorder”, Angarita et al 2021
  • “Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes”, Albogami et al 2021
  • “Amylin As a Future Obesity Treatment”, Dehestani et al 2021
  • “Efficacy and Safety of AM833 [Cagrilintide] for Weight Loss: A Dose-Finding Trial in Adults With Overweight/Obesity [Abstract]”, Lau et al 2020
  • “GLP-1R Agonists for the Treatment of Obesity: a Patent Review (2015–present)”, Liu et al 2020
  • “Semaglutide 2.4 Mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5”, Kushner et al 2020
  • “Activation of GLP-1 Receptors Attenuates Oxycodone Taking and Seeking without Compromising the Antinociceptive Effects of Oxycodone in Rats”, Zhang et al 2020
  • “Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States”, Weiss et al 2020
  • “Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol”, Eren-Yazicioglu et al 2020
  • “Management Of Endocrine Disease: Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes?”, Nauck & Meier2019
  • “Comparative Efficacy, Safety, and Cardiovascular Outcomes With Once-Weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes: Insights from the SUSTAIN 1–7 Trials”, Aroda et al 2019
  • “FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes”, FDA 2019
  • “PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes”, Aroda et al 2019b
  • “Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): a Randomized, Double-Blind, Phase 3a Trial”, Pratley et al 2019
  • “Glucagon-Like Peptide-1 Receptors within the Nucleus of the Solitary Tract Regulate Alcohol-Mediated Behaviors in Rodents”, Vallöf et al 2019
  • “The Discovery and Development of Liraglutide and Semaglutide”, Knudsen & Lau2019
  • “Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism”, Järvinen et al 2019
  • “Effects of Glucagon-Like Peptide 1 Analogs on Alcohol Intake in Alcohol-Preferring Vervet Monkeys”, Thomsen et al 2019
  • “Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial”, Rosenstock et al 2019
  • “The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Substance Use Disorder (SUD)-Related Behavioral Effects of Drugs and Alcohol: A Systematic Review”, Brunchmann et al 2019
  • “Glucagon, GLP-1 and Thermogenesis”, González-García et al 2019
  • “Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide”, Abramson et al 2019
  • “Longer-Term Liraglutide Administration at the Highest Dose Approved for Obesity Increases Reward-Related Orbitofrontal Cortex Activation in Response to Food Cues: Implications for Plateauing Weight Loss in Response to Anti-Obesity Therapies”, Farr et al 2019
  • “Glucagon Regulation of Energy Expenditure”, Kleinert et al 2019
  • “Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects With Type 2 Diabetes”, Granhall et al 2018
  • “Glucagon-Like Peptide-1 Receptor Agonists for Antipsychotic-Associated Cardio-Metabolic Risk Factors: A Systematic Review and Individual Participant Data Meta-Analysis”, Siskind et al 2018
  • “Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity: a Randomized, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial”, O’Neil et al 2018
  • “Liraglutide for Psychiatric Disorders: Clinical Evidence and Challenges”, Camkurt et al 2018
  • “Semaglutide versus Dulaglutide Once Weekly in Patients With Type 2 Diabetes (SUSTAIN 7): a Randomised, Open-Label, Phase 3b Trial”, Pratley et al 2018
  • “Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses With Once-Weekly Semaglutide Versus Dulaglutide in the United States”, Wilkinson et al 2018
  • “Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Attenuates Cocaine Seeking in Rats”, Hernandez et al 2018
  • “Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”, Davies et al 2017
  • “Effects of Liraglutide on Weight, Satiation, and Gastric Functions in Obesity: a Randomised, Placebo-Controlled Pilot Trial”, Halawi et al 2017
  • “Effects of Once-Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity”, Blundell et al 2017
  • “Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes”, Marso et al 2016
  • “Unimolecular Polypharmacy for Treatment of Diabetes and Obesity”, Tschöp et al 2016
  • “Neurobehavioral Effects of Liraglutide and Sitagliptin in Experimental Models”, Kamble et al 2016
  • “A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes”, Nauck et al 2016
  • “Glucagon Increases Energy Expenditure Independently of Brown Adipose Tissue Activation in Humans”, Salem et al 2016
  • “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”, Lau et al 2015
  • “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Prevents Development of Tolerance to Anti-Anxiety Effect of Ethanol and Withdrawal-Induced Anxiety in Rats”, Sharma et al 2014
  • “An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists—Available Efficacy and Safety Data and Perspectives for the Future”, Madsbad et al 2011
  • “Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4”, Kanoski et al 2011
  • “Associations of Semaglutide With First-Time Diagnosis of Alzheimer’s Disease in Patients With Type 2 Diabetes: Target Trial Emulation Using Nationwide Real-World Data in the US”
  • “Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials”
  • “Risk of Major Adverse Cardiovascular Events and All-Cause Mortality under Treatment With GLP-1 RAs or the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Overweight or Obese Adults without Diabetes: a Systematic Review and Meta-Analysis”
  • “Liraglutide Suppresses TNF-Α-Induced Degradation of Extracellular Matrix in Human Chondrocytes: a Therapeutic Implication in Osteoarthritis”
  • “Liraglutide, a Glucagon-Like Peptide 1 Receptor Agonist, Exerts Analgesic, Anti-Inflammatory and Anti-Degradative Actions in Osteoarthritis”
  • “Society Is Fixed, Biology Is Mutable”
  • “Should You Take Metformin for Longevity?”
  • “Obesity’s Relationship With Type 2 Diabetes Is Really Weird”
  • “The Future of Weight Loss”
  • “Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes”
  • “12-Month Neurological and Psychiatric Outcomes of Semaglutide Use for Type 2 Diabetes: a Propensity-Score Matched Cohort Study”
  • “Ozempic Is About to Be Old News”
  • “It’s the Age of Ozempic. Do We Need Weight Watchers Anymore?”
  • Sort By Magic
    • weight-loss-drugs
    • addiction-treatment mental-health diabetes-drugs behavior-modulation mood-regulation semaglutide-effects
    • weight-management
    • semaglutide-research obesity-treatment glp-1-analogs weight-loss medications clinical-efficacy
    • glp-1-therapy glucagon-receptors obesity-drugs reward-regulation substance-use
  • Wikipedia
• Miscellaneous
• Bibliography